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($17 billion) 2. Until recently, patients with meta-
static disease had limited treatment options, and their 
5-year survival was approximately 20% 3. Moreover, 
tumours in r c c rarely responded to chemotherapy and 
radiotherapy 3. Cytokine therapy (interferon alfa or 
interleukin 2) had modest efficacy, with a response 
rate of 12% and a median survival of 13 months in a 
recent meta-analysis 4. However, since the develop-
ment of molecularly targeted therapies (Table i) that 
inhibit the pathways important in the pathogenesis of 
r c c  (Figure 1), the outlook has improved.
2.  DISCUSSION
2.1  Epidemiology and Biology of r c c
Loss of the von Hippel–Lindau (v h l ) tumour suppressor 
is a pivotal event in both hereditary and sporadic r c c  
(Figure 1) 3,11. The resultant overactivity of the hypoxia- 
inducible factor (h i f ) pathway leads to overexpression 
of a set of hypoxia-related genes [for example, vascular 
endothelial growth factor, platelet-derived growth 
factor Β (p d g f r b )] and activation of a number of path-
ways [for example, the phosphoinositide-3-kinase 
(PI3K)/protein kinase B (Akt)/mammalian target of 
rapamycin (mt o r ) and ras signal transduction protein 
(Ras)/protein encoded by the murine leukemia viral 
oncogene homolog (Raf)/mitogen-activated protein 
kinase (Mek)/extracellular signal-regulated kinase 
(Erk) pathways] 12. Signalling through mt o r  is present 
in most clear-cell r c c  13,14. In addition to effects on 
tumour proliferation, angiogenesis, and apoptosis, 
activation of mt o r  may also potentiate the activity of 
h i f  12. Inhibition of mt o r  results in tumour inhibition 
in vitro 13 and in vivo 15.
Interestingly, the epithelial growth factor recep-
tor (e g f r) pathway is also important to renal onco-
genesis. Expression of e g f r  occurs at high frequency 
in r c c  (70%–90%) 16–18, and loss of v h l causes in-
creased expression of transforming growth factor α 19 
through h i f-2α–dependent mechanisms 20–22. Inhibi-
tion of this dysregulated autocrine loop is sufficient 
to reduce or abolish tumour growth in multiple 
v h l –/– r c c  cell lines 20,21.
ABSTRACT
The development of molecularly targeted agents that 
inhibit pathways critical to the development of renal 
cell carcinoma has significantly improved outcomes 
in patients with these cancers. Compelling scientific 
and phase iii data have made the use of molecularly 
targeted agents the standard of care in first-line treat-
ment. Now, available data show that re-treating patients 
with other tyrosine kinase inhibitors after they progress 
on sunitinib or sorafenib, or both, is beneficial. A large 
phase iii trial recently showed that, as compared with 
placebo, treatment with everolimus, an inhibitor of the 
mammalian target of rapamycin (mt o r ), almost halved 
the risk of progression (37% vs. 65%) and doubled 
the median progression-free survival (4 months vs. 
2 months). Overall survival was not improved in that 
study, likely reflecting treatment crossover in the pla-
cebo arm, but these data position everolimus as the 
second-line standard of care. A consistent and growing 
body of literature also suggests that re-treatment with 
other kinase inhibitors that the patient has not previ-
ously encountered is a reasonable option. Outcomes of 
initial treatment with sunitinib or sorafenib (or both) 
should not deter the use of second-line targeted therapy, 
because the first-line use of targeted agents does not 
appear to be predictive of outcomes with second-line 
therapy. However, in view of poor absolute outcomes 
after second-line treatment and the benefits seen with 
rationally developed targeted agents in the first-line 
setting, enrolment of second- and subsequent-line 
patients in further trials would be preferable.
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1.  INTRODUCTION
In 2005, renal cell carcinoma (r c c) was the ninth most 
common cancer in Canada, with an incidence of 1 
per 10,000 population 1, and in that year, the disease 
was responsible for 2% of the total cost of cancer GAN et al.
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f i g u r e  1  Simplified schema of signalling pathways that contribute to renal oncogenesis. V h l  = Von Hippel–Lindau tumour-suppressor pro-
tein; e g f r = epidermal growth factor receptor; h d a C  = histone deacetylase; Hsp90 = heat shock protein 90; h i f  = hypoxia-inducible factor; 
t g fα = transforming growth factor α; r t ks = receptor tyrosine kinases; i g f r -1 = insulin-like growth factor receptor 1; V e g f = vascular 
endothelial growth factor; Raf = protein encoded by the murine leukemia viral oncogene homolog; Ras = ras signal transduction protein; 
p i3K = phosphoinositide-3-kinase; m e k  = mitogen-activated protein kinase; p t e n = protein encoded by the phosphatase and tensin homolog 
gene; e r k = extracellular signal-regulated kinase; Akt = protein kinase B; mt O r  = mammalian target of rapamycin.
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2.2  First-line Treatment with a Targeted Agent
Treatment with a number of targeted agents (Table i) is 
now accepted as the standard of care in patients with 
metastatic r c c . In untreated patients, sunitinib 23, 
temsirolimus 24, and bevacizumab (when combined 
with interferon alfa) 25 were all found to be superior to 
interferon alfa alone. For example, Motzer et al. and 
Cella et al. 23,26 showed that patients treated with suni-
tinib experienced improved progression-free survival 
[p f s: 11 months vs. 5 months; hazard ratio (h r ): 0.42; 
95% confidence interval (c i): 0.32 to 0.54; p < 0.001), 
an improved objective response rate (o r r : 31% vs. 
6%; p < 0.001), and improved quality of life. Similar 
benefits were also seen in patients who had received 
prior cytokine therapy 27. In that group, treatment with 
sorafenib was superior to placebo with regard to p f s 
(6 months vs. 3 months; h r : 0.44; 95% c i: 0.35 to 
0.55; p < 0.01) and the disease control rate (84% vs. 
55%; p < 0.001). Quality of life was also improved in 
patients receiving sorafenib as compared with those 
receiving placebo 28. Only the e g f r  inhibitors failed to 
deliver substantial therapeutic benefit, either as single 
agents 17,18,29–31 or in combination with agents such 
as bevacizumab 32.
2.3  Second-line Treatment After Failure with a First-
line Targeted Agent
Until recently, little evidence was available to guide 
therapy once patients had progressed on first-line 
treatment with a targeted agent. There is certainly a 
need to offer treatments to this patient population, not 
uncommonly encountered in clinical practice and of-
ten of appropriate performance status to tolerate more 
therapy. Re-treatment with another targeted agent 
has become commonplace practice despite the lack 
of prospective data 33, and a number of retrospective 
studies have now been published about this approach 
(Table ii). In all but two reports, the clinical benefit 
rate (complete response/partial response/stable dis-
ease) exceeded 50%, and in most cases, it reached 
70% or better. In most reports, the median duration 
of benefit was 6 months or more. Re-treatment was 
generally well tolerated, with the most common grade 
3 toxicities being fatigue, hypertension, and hand–
foot syndrome.
Prior response to first-line targeted treatment did 
not predict response to second-line treatment 34–37. 
As with other targeted therapies 38, this lack of cross-
resistance is thought to indicate incomplete suppression 
t a b l e  i  Selected targeted agents in the treatment of renal cell carcinoma (r c c )
  Name  Targets  Canadian regulatory status in r C C
Tyrosine kinase inhibitors
Sunitinib 5   v e g f r  1, 2, 3;    Approved for patients with metastatic r c c  of clear-cell histology and 
(Sutenta)    p d g f r a , b; Flt3;  good or intermediate prognosis
    c-Kit; r e t
 
Sorafenib 6,7    Raf; v e g f r 2, 3;    Approved for patients with locally advanced or metastatic r c c  who have
(Nexacarb)  p d g f r b ; Flt3;   failed, or are intolerant to, cytokine therapy
    c-Kit; r e t
Temsirolimus 8 m t o r   Approved for patients with metastatic r c c  (not funded in all provinces)
(Toriselc)
  
Axitinib 9   v e g f r 1, 2, 3;  Not approved
(Pfizera)    p d g f r a , b; c-Kit
 
Everolimus 8   mt o r   Under consideration
(Certicand)
  
Monoclonal antibodies
Bevacizumab 10  v e g f   Not approved
(Avastine)
  
a  Pfizer Canada, Kirkland, QC.
b  Bayer HealthCare AG, Leverkusen, Germany.
c  Wyeth, Madison, NJ, U.S.A.
d  Novartis Pharmaceuticals, St. Louis, MO, U.S.A.
e  Genentech, San Francisco, CA, U.S.A., and Hoffmann–La Roche Ltd., Mississauga, ON.
v e g f r  = vascular endothelial growth factor receptor; p d g f r a , b = platelet-derived growth factor receptor α and Β; Flt3 = fms-related  
tyrosine kinase 3; Raf = protein encoded by the murine leukemia viral oncogene homolog;  mt o r  = mammalian target of rapamycin;  
v e g f  = vascular endothelial growth factor.GAN et al.
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t a b l e  ii  Retrospective data regarding the efficacy of second-line targeted therapy
 Reference  Pts                            Targeted treatment                      Clinical benefit  Benefit  Frequency
   (n)  First-line  Second-line+  (%)  (CR/PR/SD)  duration  of grades 3 and 4 
             (n)  (months)  toxicities
First-line sunitinib             
Sablin et al., 2007 40  22  Sunitinib  Sorafenib  70  0/15/55  p f s: 6  n a
Sepulveda, et al., 2008 41  20  Sunitinib  Sorafenib  70  0/10/60  t t p: 7  Fatigue (17%)
     plus cytokines (100%)        o s : 9  Mucositis (9%)
                 Hypertension (9%)
                 h f s  (9%)
Dudek et al., 2009 42  20  Sunitinib  Sorafenib  35    t t p: 2  n a
     plus cytokines (80%)         
First-line sorafenib             
Sablin et al., 2007 40  68  Sorafenib  Sunitinib  73  0/15/58  p f s: 7  n a
Eichelberg et al., 2008 43  30  Sorafenib  Sunitinib  55  0/11/44  p f s: 10  h f s  (3%)
     plus cytokines (67%)          Leucopenia (3%)
                 Platelets (3%)
Dudek et al., 2009 42  29  Sorafenib  Sunitinib  59  0/21/38  t t p: 5  n a
     plus cytokines (55%)         
First-line sorafenib + sunitinib            
Rini et al., 2007 44  62  Sorafenib (100%)  Axitinib  55  0/21/34  p f s: 7  Fatigue (18%)
     plus sunitinib (23%)          Hypertension (16%)
     plus cytokines (60%)          h f s  (11%)
Dutcher et al., 2008 45  59  Sorafenib  Axitinib  100  0/32/68  p f s:  Fatigue (13%)
     plus sunitinib (24%)        approx. 8  Hypertension (11%)
     plus cytokines (64%)          h f s  (11%)
Whorf et al., 2008 46  29  Sorafenib (n=12),  Bevacizumab  84  0/19/65  p f s: 11  Proteinuria (17%)
     sunitinib (n=15),  and        Fatigue (7%)
     both (n=2)  everolimus        Stomatitis (7%)
First-line bevacizumab             
Knox et al., 2007 37  197  Bevacizumab  Sorafenib  81  0/3/78  n a   n a
     plus others (100%)         
Rini et al., 2008 35  61  Bevacizumab  Sunitinib  82  0/23/59  p f s: 8  Fatigue (34%)
     plus others (66%)        o s : 12  Hypertension (18%)
                 h f s  (10%)
Other first-line             
Rini et al., 2008 36  37  Bevacizumab (n=15)  Sorafenib  43  0/3/40  p f s: 4  h f s  (31%)
     or sunitinib (n=22)          Fatigue (17%)
     plus other           Hypertension (14%) 
     anti-angiogenics (13%)
     plus cytokines  
     or others (72%)         
Tamaskar et al., 2008 34  30  Miscellaneous  Sunitinib  81  0/56/25  t t p: 10  n a
     (thalidomide, lenalidomide,  (n=16)       
     bevacizumab, volociximab,  Sorafenib  71  0/7/64   
     AG13736, sorafenib,   (n=14) 
     or sunitinib)     
Pts = patients; c r  = complete response; p r = partial response; s d = stable disease; p f s = progression-free survival; n a  = not available;  
t t p = time to progression; o s  = overall survival; h f s  = hand–foot syndrome.SECOND-LINE AFTER INITIAL TARGETED THERAPY FOR RCC
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of tumour pathways with initial therapy. Further evi-
dence of activity has been provided by the large 
prospective expanded-access programs of sorafenib 37 
and sunitinib 39, which reported on 2488 and 2341 
patients respectively. These programs showed that 
clinical benefit rates in these populations (84% and 
52% respectively) were similar to those reported in 
phase iii trials. A substantial minority of patients 
previously exposed to targeted therapies also ap-
peared to derive benefit from sunitinib and sorafenib 
in these programs.
The best evidence to date is provided by Motzer 
et al. 47, who reported a positive phase iii trial in 
this clinical setting. Patients who had progressed on 
sunitinib or sorafenib (or both) were randomized to 
either the mt o r  inhibitor everolimus (10 mg orally, 
once daily) or to placebo. Although patients from 
all prognostic groups were enrolled into the trial, 
approximately half the patients had an intermediate 
prognosis. The primary endpoint was p f s as deter-
mined by independent reviewers. The trial was halted 
early when an interim analysis indicated a substan-
tial and significant difference in p f s in favour of the 
everolimus group. The progression rate was 37% in 
the everolimus group as compared with 65% in the 
placebo group (h r : 0.30; 95% c i : 0.22 to 0.40; p < 
0.0001). Median p f s was 4.0 months (95% c i : 3.7 to 
5.5 months) in the everolimus group as compared 
with 1.9 months (95% c i : 1.8 to 1.9 months) in the 
control group. Median overall survival (o s ) had not 
been reached in the everolimus arm (in excess of 10 
months as compared with 8.8 months in the placebo 
group). The difference in o s  did not reach statistical 
significance, likely as a result of the planned cross-
over from placebo to everolimus on study. Although 
more stomatitis (40% vs. 8%), rash (25% vs. 4%), 
and fatigue (20% vs. 16%) occurred in the everolimus 
group, these side effects were mostly mild or moder-
ate in severity. Pneumonitis (any grade) was detected 
in 22 patients in the everolimus group (8%), but only 
8 patients 3 had grade 3 pneumonitis. Quality of life 
was equivalent in both study arms.
At this time, everolimus can reasonably be con-
sidered to be the preferred second-line treatment after 
initial failure of sunitinib or sorafenib. Although o s  
is always preferable as the primary endpoint in phase 
iii trials, the use of p f s in the Motzer study is an ac-
ceptable surrogate, and the overall case supporting 
the efficacy of everolimus as a second-line treatment 
is strong 48. Although everolimus is not yet approved 
in Canada for metastatic r c c , temsirolimus could be 
considered in this setting, given that it is currently 
approved in Canada and has a similar mechanism 
of activity. Once completed, two phase iii trials cur-
rently in progress may affect this choice. The first 
randomizes patients to temsirolimus or sorafenib as 
second-line therapy after progression on sunitinib 
(search for “NCT00474786” at www.clinicaltrials.
gov/ct2/search). The second randomizes patients who 
failed a previous systemic treatment, which may be a 
tyrosine kinase inhibitor, to either sorafenib or axitinib 
(search for “NCT00678392” at www.clinicaltrials.
gov/ct2/search).
3.  CONCLUSIONS
Inhibitors of multiple kinases such as sunitinib and 
sorafenib are now established as standard first-line 
therapy in patients with r c c . When disease progres-
sion occurs after such therapy, there is clearly more 
benefit to be gained by re-treating these patients with 
another targeted agent. Everolimus is the drug of 
choice at the present time, and we expect it to obtain 
approval for this indication in Canada soon. Until 
such time as approval is forthcoming, temsirolimus 
(if available) could be substituted, given its similar 
mechanism of action. It would also not be unreason-
able to use any of the targeted agents in Table ii (if 
available) to treat patients with progressive r c c  who 
have not previously been exposed to those agents. 
However, the benefits seen with rationally-developed 
targeted agents in the first-line setting strongly suggest 
that it is more appropriate to enrol those patients into 
clinical trials. Research priorities include the evalu-
ation of predictive biomarkers to allow for patient 
enrichment, optimization of drug sequencing [con-
current vs. sequential, and simultaneous blockade at 
several points of the same pathway (vertical blockade) 
vs. blockade of several collateral pathways (horizon-
tal blockade)], and identification of other effective 
drugs—for example, histone deacetylase 49,50.
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